

1 **Title:** Chimeric antigen receptors that trigger phagocytosis

2

3 **Authors:** Meghan A. Morrissey<sup>1,2‡</sup>, Adam P. Williamson<sup>1,2‡</sup>, Adriana M. Steinbach<sup>1,2</sup>,  
4 Edward W. Roberts<sup>3</sup>, Nadja Kern<sup>1,2</sup>, Mark B. Headley<sup>3</sup> and Ronald D. Vale<sup>1,2\*</sup>.

5

6 <sup>1</sup>Department of Cellular and Molecular Pharmacology, University of California San  
7 Francisco, San Francisco, CA 94158

8

9 <sup>2</sup>Howard Hughes Medical Institute, University of California San Francisco, San  
10 Francisco, CA 94158

11

12 <sup>3</sup>Department of Pathology, University of California San Francisco, 513 Parnassus  
13 Avenue, San Francisco, CA 94143

14

15 ‡ denotes co-first authors

16 \*Address correspondence to: ron.vale@ucsf.edu

17

18

19 **Abstract**

20

21 Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T cells to kill  
22 cancer. The success of CAR-T cell therapies highlights the promise of programmed  
23 immunity and suggests that applying CAR strategies to other immune cell lineages may  
24 be beneficial. Here, we engineered a family of Chimeric Antigen Receptors for  
25 Phagocytosis (CAR-Ps) that direct macrophages to engulf specific targets, including  
26 cancer cells. CAR-Ps consist of an extracellular antibody fragment, which can be  
27 modified to direct CAR-P activity towards specific antigens. By screening a panel of  
28 engulfment receptor intracellular domains, we found that the cytosolic domains from  
29 Megf10 and FcR $\gamma$  robustly triggered engulfment independently of their native  
30 extracellular domain. We show that CAR-Ps drive specific engulfment of antigen-coated  
31 synthetic particles and whole human cancer cells. Addition of a tandem PI3K  
32 recruitment domain increased cancer cell engulfment. Finally, we show that CAR-P  
33 expressing murine macrophages reduce cancer cell number in co-culture by over 40%.

34

35 **Summary (15-30 words)**

36

37 We report the first Chimeric Antigen Receptors for Phagocytosis (CAR-Ps) that promote  
38 engulfment of antigen-coated particles and cancer cells.

39

40

41 **Introduction**

42

43 Chimeric antigen receptors (CARs) are synthetic transmembrane receptors that redirect  
44 T cell activity towards clinically relevant targets (reviewed in (Lim et al. 2017; Fesnak,  
45 June, and Levine 2016)). The CAR-T receptor contains an extracellular single chain  
46 antibody fragment (scFv) that recognizes known tumor antigens, and intracellular  
47 signaling domains from the T Cell Receptor (TCR) and costimulatory molecules that  
48 trigger T cell activation (Fesnak, June, and Levine 2016; Kochenderfer et al. 2009).  
49 CAR-T cells recognizing CD19, a marker expressed at high levels on the surface of B  
50 cells and B cell-derived malignancies, have been used successfully to target  
51 hematological malignancies with 70-90% of patients showing measurable improvement  
52 (Lim et al. 2017; Engel et al. 1995; Haso et al. 2013). The success of CAR-T suggests  
53 that programming immune cells to target cancer might be a broadly applicable  
54 approach.

55

56 Macrophages are critical effectors of the innate immune system, responsible for  
57 engulfing debris and pathogens. Harnessing macrophages to combat tumor growth is of  
58 longstanding interest (C. Alvey and Discher 2017; Lee et al. 2016). Macrophages are  
59 uniquely capable of penetrating solid tumors, while other immune cells, like T cells, are  
60 physically excluded or inactivated (Lim et al. 2017; Lee et al. 2016). This suggests that  
61 engineered macrophages may augment existing T cell-based therapies. Early efforts  
62 transferring healthy macrophages into cancer patients failed to inhibit tumor growth,  
63 suggesting that macrophages require additional signals to direct their activity towards  
64 tumors (Lacerna, Stevenson, and Stevenson 1988; Andreesen et al. 1990). Antibody  
65 blockade of CD47, a negative regulator of phagocytosis, reduced tumor burden,  
66 indicating that shifting the balance in favor of macrophage activation and engulfment is  
67 a promising therapeutic avenue (Majeti et al. 2009; Chao et al. 2010; Jaiswal et al.  
68 2009; Tseng et al. 2013). Here, we report a family of chimeric antigen receptors that  
69 activate phagocytosis of cancer cells based on recognition of defined cell surface  
70 markers, resulting in significantly reduced cancer cell growth.

71

## 72 **Results**

73

74 To program engulfment towards a target antigen, we created a CAR strategy using the  
75 CAR-T design as a guide (Fesnak, June, and Levine 2016). We call this new class of  
76 synthetic receptors Chimeric Antigen Receptors for Phagocytosis (CAR-Ps). The CAR-  
77 P molecules contain the extracellular single-chain antibody variable fragment (scFv)  
78 recognizing the B cell antigen CD19 ( $\alpha$ CD19) and the CD8 transmembrane domain  
79 present in the  $\alpha$ CD19 CAR-T (Fesnak, June, and Levine 2016; Kochenderfer et al.  
80 2009). To identify cytoplasmic domains capable of promoting phagocytosis, we  
81 screened a library of known murine phagocytic receptors: Megf10 (Figure 1a), the  
82 common  $\gamma$  subunit of Fc receptors (FcR $\gamma$ ), Bai1, and MerTK (Penberthy and  
83 Ravichandran 2016). FcR triggers engulfment of antibody-bound particles, while the  
84 other receptors recognize apoptotic corpses (Freeman and Grinstein 2014; Penberthy  
85 and Ravichandran 2016). We also made a receptor containing an extracellular  $\alpha$ CD19  
86 antibody fragment and a cytoplasmic GFP, but no signaling domain, to test whether  
87 adhesion mediated by the  $\alpha$ CD19 antibody fragment is sufficient to induce engulfment  
88 (Figure 1a; CAR-P<sup>GFP</sup>).

89

90 To assay our library of CAR-Ps, we introduced each CAR-P into J774A.1 murine  
91 macrophages by lentiviral infection. As an engulfment target, we used 5  $\mu$ m diameter  
92 silica beads coated with a supported lipid bilayer. A His<sub>8</sub>-tagged extracellular domain of  
93 CD19 was bound to a NiNTA-lipid incorporated into the supported lipid bilayers.  
94 Macrophages expressing a CAR-P with the Megf10 (CAR-P<sup>Megf10</sup>) or FcR $\gamma$  (CAR-P<sup>FcR $\gamma$</sup> )  
95 intracellular domain promoted significant engulfment of CD19 beads compared to  
96 macrophages with no CAR (Figure 1b, c, video 1). Macrophages expressing CAR-P<sup>Bai1</sup>,  
97 CAR-P<sup>MerTK</sup>, and the adhesion-only CAR-P<sup>GFP</sup> did not bind the CD19 beads even  
98 though these CAR-Ps are present at the cell surface (Figure 1b, c, figure supplement 1).  
99 To confirm that the CAR-P was a viable strategy for redirecting primary macrophages,  
100 we expressed the CAR-P<sup>FcR $\gamma$</sup>  in primary murine bone marrow derived macrophages and  
101 found that these transfected primary cells also were able to trigger engulfment of CD19  
102 beads (Figure 1d).

103

104

105 Next we asked if the CAR-P strategy could target a different antigen. Because CAR-  
106  $P^{Mef10}$  performed well in our initial screen (Figure 1a), we developed  $\alpha$ CD22 CAR-  
107  $P^{Mef10}$  using a previously developed  $\alpha$ CD22 antibody fragment (Xiao et al. 2009; Haso  
108 et al. 2013). Consistent with our results using  $\alpha$ CD19-based CARs,  $\alpha$ CD22 CAR- $P^{Mef10}$   
109 promoted engulfment of CD22 beads (Figure 2a). To confirm antigen specificity of CAR-  
110 P, we incubated  $\alpha$ CD19 CAR- $P^{Mef10}$  macrophages with CD22 beads, and  $\alpha$ CD22 CAR-  
111  $P^{Mef10}$  macrophages with CD19 beads. CD19 beads were not eaten by  $\alpha$ CD22 CAR-  
112  $P^{Mef10}$  macrophages, and CD22 beads were not eaten by  $\alpha$ CD19 CAR- $P^{Mef10}$   
113 macrophages (Figure 2a). These data indicate that CAR- $P^{Mef10}$  specifically triggers  
114 engulfment in response to the target ligand and that the CAR-P strategy is able to target  
115 multiple cancer antigens.

116

117 To further define the capabilities of the CAR-P, we assessed the capacity of CAR-P-  
118 expressing macrophages to engulf variably sized targets. We found that CAR- $P^{Mef10}$   
119 was able to trigger specific engulfment of beads ranging from 2.5  $\mu$ m to 20  $\mu$ m in  
120 diameter, with higher specificity above background engulfment being demonstrated for  
121 the larger beads (Figure 2b). The high background in this assay is due to heterogeneity  
122 in the bilayers on beads purchased from a different manufacturer (Corpuscular) than  
123 previous assays. For the 10  $\mu$ m bead condition, we also tested the phagocytic efficiency  
124 of beads containing the endogenous Mef10 ligand, phosphatidylserine. We found that  
125 CAR- $P^{Mef10}$  macrophages engulfed CD19 beads and beads containing 10%  
126 phosphatidylserine and the adhesion molecule ICAM-1 at a similar frequency (Fig 2b).  
127 This indicates that the CAR-P is comparably efficient to the endogenous system.

128

129 To determine if the CAR- $P^{Mef10}$  initiates active signaling at the synapse between the  
130 macrophage and target, we stained for phosphotyrosine. Macrophages expressing  
131 CAR- $P^{Mef10}$  exhibited an increase in phosphotyrosine at the synapse, while  
132 macrophages expressing CAR- $P^{GFP}$  did not show this enrichment (Figure 3a).

133 Consistent with previous reports, we found that F-actin also was enriched at the cell

134 bead synapse (Figure 3- figure supplement 1). This result suggests that CAR-P<sup>Megf10</sup>  
135 initiates engulfment through a localized signaling cascade involving tyrosine  
136 phosphorylation.

137

138 Both successful CAR-P intracellular domains (from FcR $\gamma$  and Megf10) have cytosolic  
139 Immunoreceptor Tyrosine-based Activation Motifs (ITAMs) that are phosphorylated by  
140 Src family kinases. Based on this observation, we hypothesized that the expression of  
141 an alternate ITAM-containing receptor might initiate phagocytosis when expressed in  
142 macrophages. The CD3 $\zeta$  subunit of the T cell receptor contains three ITAM motifs. To  
143 test if the CD3 $\zeta$  chain was able to activate phagocytic signaling, we transduced  
144 macrophages with the first generation CAR-T (Figure 3b). The CAR-T was able to  
145 trigger engulfment of CD19 beads to a comparable extent as CAR-P<sup>Megf10</sup> (Figure 3c). In  
146 T cells, phosphorylated ITAMs in CD3 $\zeta$  bind to tandem SH2 domains (tSH2) in the  
147 kinase ZAP70. Zap70 is not expressed in macrophages, but Syk, a phagocytic signaling  
148 effector and tSH2 domain containing protein, is expressed at high levels (Andreu et al.  
149 2017). Previous work suggested that Syk kinase can also bind to the CD3 $\zeta$  ITAMs (Bu,  
150 Shaw, and Chan 1995), indicating that the CAR-T may promote engulfment through a  
151 similar mechanism as CAR-P<sup>FcR $\gamma$</sup> . To quantitatively compare the interaction between  
152 Syk<sup>tSH2</sup> and CD3 $\zeta$  or FcR $\gamma$  in a membrane proximal system recapitulating physiological  
153 geometry, we used a liposome-based assay (Figure 3d (Hui and Vale 2014)). In this  
154 system, His<sub>10</sub>-CD3 $\zeta$  and His<sub>10</sub>-Lck (the kinase that phosphorylates CD3 $\zeta$ ) are bound to a  
155 liposome via NiNTA-lipids and the binding of labeled tandem SH2 domains to  
156 phosphorylated CD3 $\zeta$  was measured using fluorescence quenching. Our results show  
157 that Syk-tSH2 binds the CD3 $\zeta$  and FcR $\gamma$  with comparable affinity (~15 nM and ~30 nM  
158 respectively, Figure 3d). Collectively, these results demonstrate that the TCR CD3 $\zeta$   
159 chain can promote phagocytosis in a CAR-P, likely through the recruitment of Syk  
160 kinase.

161

162 We next sought to program engulfment towards a cellular target. We incubated the  
163 CAR-P<sup>Megf10</sup> and CAR-P<sup>FcR $\gamma$</sup>  macrophages with cancerous Raji B cells that express high  
164 levels of endogenous CD19. Strikingly, the majority of CAR-P-expressing macrophages

165 internalized bites of the target cell (Figure 4a, video 1, 78% of CAR-P<sup>Megf10</sup> and 85% of  
166 CAR-P<sup>FcRy</sup> macrophages internalized bites within 90 min). The biting phenotype  
167 resembles trogocytosis, or nibbling of live cells, which has been reported previously in  
168 immune cells (Joly and Hudrisier 2003). This process was dependent on the ITAM-  
169 bearing intracellular signaling domain, as removing the signaling domain (CAR-P<sup>GFP</sup>)  
170 dramatically reduced trogocytosis (Figure 4a). Enrichment of phosphotyrosine at the  
171 cell-cell synapse further supports active signaling initiating trogocytosis (Figure 4- figure  
172 supplement 1). The CAR-P module also was able to induce trogocytosis in non-  
173 professional phagocytes, human NIH 3T3 fibroblast cells (Figure 4- figure supplement  
174 2). This suggests that the CAR-P can promote cancer antigen-dependent engulfment by  
175 both professional and non-professional phagocytes.

176

177 We next focused on engineering strategies to engulf whole human cancer cells. We  
178 observed that macrophages expressing the CAR-P<sup>Megf10</sup> or CAR-P<sup>FcRy</sup> were capable of  
179 engulfing whole Raji B cells (2 cancer cells eaten per 100 macrophages in a 4-8 hr  
180 window for both CAR-P<sup>Megf10</sup> or CAR-P<sup>FcRy</sup>, Fig 4b,e, video 2). Whole cell engulfment  
181 was infrequent but trogocytosis was robust, suggesting that productive macrophage  
182 target interactions were frequently insufficient to trigger whole cell engulfment. To  
183 determine if whole cell eating could be enhanced by further opsonization of CD19, we  
184 opsonized Raji B cells with a mouse IgG2a anti-CD19 antibody. While addition of this  
185 antibody did not trigger additional whole cell internalization, blockade of the “don’t eat  
186 me” signal CD47 using the mouse IgG1 anti-human B6H12 clone resulted in a 2.5 fold  
187 increase of whole cell eating of opsonized Raji B cells (Figure 4- figure supplement 3).  
188 Both endogenous FcR recognition of the anti-CD47 antibody and blockade of CD47  
189 signaling may contribute to this effect.

190

191 To develop a receptor to enhance whole cell eating, we hypothesized that combining  
192 signaling motifs in a tandem array might increase the frequency of whole cell  
193 engulfment by specifically recruiting effectors required for the engulfment of large  
194 targets. Previous work demonstrated that PI3K signaling is important for internalization  
195 of large targets (Schlam et al. 2015). To increase PI3K recruitment to the CAR-P, we

196 fused the portion of the CD19 cytoplasmic domain (amino acids 500 to 534) that recruits  
197 the p85 subunit of PI3K to the CAR-P<sup>FcRy</sup> creating a “tandem” CAR (CAR-P<sup>tandem</sup>, Fig  
198 4c) (Tuveson et al 1993, Brooks et al 2004). A CAR-P containing the p85 recruitment  
199 motif alone (CAR-P<sup>PI3K</sup>) was able to induce some whole cell engulfment, comparable to  
200 the CAR-P<sup>FcRy</sup> (Fig 4e). Expression of CAR-P<sup>tandem</sup> tripled the ability of macrophages to  
201 ingest whole cells compared to CAR-P<sup>GFP</sup> (6 cancer cells eaten per 100 macrophages,  
202 Figure 4d,e, video 3). These data indicate that assembling an array of motifs designed  
203 to recruit distinct phagocytic effectors can increase CAR-P activity towards whole cells.  
204

205 To determine if the combination of whole cell eating and trogocytosis was sufficient to  
206 drive a noticeable reduction in cancer cell number, we incubated CAR-P macrophages  
207 with Raji B cells for two days. After 44 hr of co-culture, we found that CAR-P  
208 macrophages significantly reduced the number of Raji cells (Fig 4f). Although the CAR-  
209 P<sup>tandem</sup> was much more efficient at whole cell eating, the CAR-P<sup>FcRy</sup> performed nearly as  
210 well at eliminating Rajis. Importantly, our assay does not distinguish between whole cell  
211 engulfment or death following trogocytosis, so it is possible both CAR-P activities are  
212 contributing to Raji death rates. Overall, these data suggest that the CAR-P is a  
213 successful strategy for directing macrophages towards cancer targets, and can initiate  
214 whole cell eating and trogocytosis leading to cancer cell elimination.  
215

216 In summary, we engineered phagocytes that recognize and ingest targets through  
217 specific antibody-mediated interactions. This strategy can be directed towards multiple  
218 extracellular ligands (CD19 and CD22) and can be used with several intracellular  
219 signaling domains that contain ITAM motifs (Megf10, FcRy, and CD3ζ). Previous work  
220 has suggested that spatial segregation between Src-family kinases and an inhibitory  
221 phosphatase, driven by receptor ligation, is sufficient to trigger signaling by the T cell  
222 receptor (Davis and van der Merwe 2006; James and Vale 2012) and FcR (Freeman et  
223 al. 2016). The CAR-Ps that we have developed may similarly convert receptor-ligand  
224 binding into receptor phosphorylation of ITAM domains through partitioning of kinases  
225 and phosphatases at the membrane-membrane interface.  
226

227 Further development of CAR-Ps could be useful on several therapeutic fronts. Targeting  
228 of tumor cells by macrophages has been suggested to cause tumor cell killing (Jaiswal  
229 et al. 2009; Majeti et al. 2009; Chao et al. 2010; Jadus et al. 1996), either through  
230 directly engulfing cancer cells or by stimulating antigen presentation and a T cell-  
231 mediated response (Liu et al. 2015; Tseng et al. 2013). Inhibition of the CD47-SIRPA  
232 “Don’t eat me” signaling pathway has also been shown to result in engulfment of cancer  
233 cells (Chen et al. 2017; Gardai et al. 2005; Jaiswal et al. 2009; Majeti et al. 2009; Chao  
234 et al. 2010). A recent study suggests that CD47 inhibition is most effective when  
235 combined with a positive signal to promote target engulfment, which raises the  
236 possibility of combining CAR-P expression with CD47 or SIRPA inhibition for an additive  
237 effect (Alvey et al. 2017).

238

239 Although we were able to increase whole cell engulfment by recruiting the activating  
240 subunit of PI3K to the phagocytic synapse, the engulfment of larger 20 micron beads  
241 was more frequent than the engulfment of whole cells. We hypothesize that this is due  
242 to differing physical properties of the engulfment target. Specifically, increased target  
243 stiffness has been shown to promote engulfment, suggesting that manipulating the  
244 physical properties of the engulfment target could also be a potential strategy for  
245 increasing CAR-P efficiency (Beningo and Wang 2002; Cross et al. 2007).

246

247 While the CAR-P can engulf whole, viable cancer cells, the ingestion of a piece of the  
248 target cell is more common. Trogocytosis, or nibbling of living cells, has also been  
249 described in immune cells (Harshyne et al. 2003; Harshyne et al. 2001; Kao et al. 2006;  
250 Joly and Hudrisier 2003; Batista, Iber, and Neuberger 2001) and brain-eating amoebae  
251 (Ralston et al. 2014). In vivo studies also have shown that endogenous dendritic cell  
252 populations ingest bites of live tumor cells, contributing to presentation of cancer neo-  
253 antigen (Harshyne et al. 2001; Harshyne et al. 2003). Although we were able to use the  
254 CAR-P to induce trogocytosis in dendritic cells, we were not able to detect robust cross  
255 presentation of the model antigen ovalbumin (Figure 4- figure supplement 4). Thus,  
256 although using CAR-Ps to enhance cross presentation of cancer antigen is an intriguing

257 future avenue, such a strategy would likely require more optimization of the dendritic  
258 cell subset employed or the CAR-P receptor itself.

259

260 Overall, our study demonstrates that the CAR approach is transferrable to biological  
261 processes beyond T cell activation and that the expression of an engineered receptor in  
262 phagocytic cells is sufficient to promote specific engulfment and elimination of cancer  
263 cells.

264

265

266 **Acknowledgments**

267

268 We thank J. Reiter and E. Yu for providing mouse long bones as a source for  
269 hematopoietic stem cells. We thank K. McKinley and X. Su for critical feedback on this  
270 manuscript. M.A.M. was supported by the National Institute of General Medical  
271 Sciences of the National Institutes of Health under award number F32GM120990.  
272 A.P.W was supported by a CRI Irvington Postdoctoral Fellowship. This work was funded  
273 by the Howard Hughes Medical Institute.

274

275 **Competing Financial Interests**

276 The authors declare no competing financial interests.

277

278

279

280

281

282

283 **References**

- 284 Alvey, Cory, and Dennis E. Discher. 2017. "Engineering Macrophages to Eat Cancer:  
285 From 'marker of Self' CD47 and Phagocytosis to Differentiation." *Journal of*  
286 *Leukocyte Biology*, May, jlb.4RI1216-516R. doi:10.1189/jlb.4RI1216-516R.
- 287 Alvey, Cory M., Kyle R. Spinler, Jerome Irianto, Charlotte R. Pfeifer, Brandon Hayes,  
288 Yuntao Xia, Sangkyun Cho, et al. 2017. "SIRPA-Inhibited, Marrow-Derived  
289 Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted  
290 Regression of Solid Tumors." *Current Biology*, June.  
291 doi:10.1016/j.cub.2017.06.005.
- 292 Andreesen, R, C Scheibenbogen, W Brugger, S Krause, H G Meerpohl, H G Leser, H  
293 Engler, and G W Löhr. 1990. "Adoptive Transfer of Tumor Cytotoxic Macrophages  
294 Generated in Vitro from Circulating Blood Monocytes: A New Approach to Cancer  
295 Immunotherapy." *Cancer Research* 50 (23): 7450–56.  
296 <http://www.ncbi.nlm.nih.gov/pubmed/1701343>.
- 297 Andreu, Nuria, Jody Phelan, Paola F. de Sessions, Jacqueline M. Cliff, Taane G. Clark,  
298 and Martin L. Hibberd. 2017. "Primary Macrophages and J774 Cells Respond  
299 Differently to Infection with Mycobacterium Tuberculosis." *Scientific Reports* 7  
300 (February): 42225. doi:10.1038/srep42225.
- 301 Batista, Facundo D., Dagmar Iber, and Michael S. Neuberger. 2001. "B Cells Acquire  
302 Antigen from Target Cells after Synapse Formation." *Nature* 411 (6836). Nature  
303 Publishing Group: 489–94. doi:10.1038/35078099.
- 304 Beningo, Karen A, and Yu-li Wang. 2002. "Fc-Receptor-Mediated Phagocytosis Is  
305 Regulated by Mechanical Properties of the Target." *Journal of Cell Science* 115 (Pt  
306 4): 849–56. <http://www.ncbi.nlm.nih.gov/pubmed/11865040>.
- 307 Bu, J Y, A S Shaw, and A C Chan. 1995. "Analysis of the Interaction of ZAP-70 and Syk  
308 Protein-Tyrosine Kinases with the T-Cell Antigen Receptor by Plasmon  
309 Resonance." *Proceedings of the National Academy of Sciences of the United*

310 *States of America* 92 (11): 5106–10. <http://www.ncbi.nlm.nih.gov/pubmed/7761456>.

311 Chao, Mark P., Ash A. Alizadeh, Chad Tang, June H. Myklebust, Bindu Varghese, Saar  
312 Gill, Max Jan, et al. 2010. “Anti-CD47 Antibody Synergizes with Rituximab to  
313 Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma.” *Cell* 142 (5): 699–  
314 713. doi:10.1016/j.cell.2010.07.044.

315 Chen, Jun, Ming-Chao Zhong, Huaijian Guo, Dominique Davidson, Sabrin Mishel, Yan  
316 Lu, Inmoo Rhee, et al. 2017. “SLAMF7 Is Critical for Phagocytosis of  
317 Haematopoietic Tumour Cells via Mac-1 Integrin.” *Nature* 544 (7651): 493–97.  
318 doi:10.1038/nature22076.

319 Cross, Sarah E., Yu-Sheng Jin, Jianyu Rao, and James K. Gimzewski. 2007.  
320 “Nanomechanical Analysis of Cells from Cancer Patients.” *Nature Nanotechnology*  
321 2 (12). Nature Publishing Group: 780–83. doi:10.1038/nnano.2007.388.

322 Davis, Simon J, and P Anton van der Merwe. 2006. “The Kinetic-Segregation Model:  
323 TCR Triggering and beyond.” *Nature Immunology* 7 (8). Nature Publishing Group:  
324 803–9. doi:10.1038/ni1369.

325 Engel, Pablo, Liang Ji Zhou, David C. Ord, Shinichi Sato, Beverley Koller, and Thomas  
326 F. Tedder. 1995. “Abnormal B Lymphocyte Delevopment, Activation, and  
327 Differentiation in Mice That Lack or Overexpress the CD19 Signal Transduction  
328 Molecule.” *Immunity* 3 (1): 39–50. doi:10.1016/1074-7613(95)90157-4.

329 Fesnak, Andrew D., Carl H. June, and Bruce L. Levine. 2016. “Engineered T Cells: The  
330 Promise and Challenges of Cancer Immunotherapy.” *Nature Reviews Cancer* 16  
331 (9): 566–81. doi:10.1038/nrc.2016.97.

332 Freeman, Spencer A., Jesse Goyette, Wendy Furuya, Elliot C. Woods, Carolyn R.  
333 Bertozzi, Wolfgang Bergmeier, Boris Hinz, P. Anton Van Der Merwe, Raibatak Das,  
334 and Sergio Grinstein. 2016. “Integrins Form an Expanding Diffusional Barrier That  
335 Coordinates Phagocytosis.” *Cell* 164 (1–2): 128–40. doi:10.1016/j.cell.2015.11.048.

336 Freeman, Spencer A., and Sergio Grinstein. 2014. “Phagocytosis: Receptors, Signal

337 Integration, and the Cytoskeleton.” *Immunological Reviews* 262 (1): 193–215.  
338 doi:10.1111/imr.12212.

339 Gardai, Shyra J., Kathleen A. McPhillips, S. Courtney Frasch, William J. Janssen, Anna  
340 Starefeldt, Joanne E. Murphy-Ullrich, Donna L. Bratton, Per-Arne Arne Oldenborg,  
341 Marek Michalak, and Peter M. Henson. 2005. “Cell-Surface Calreticulin Initiates  
342 Clearance of Viable or Apoptotic Cells through Trans-Activation of LRP on the  
343 Phagocyte.” *Cell* 123 (2): 321–34. doi:10.1016/j.cell.2005.08.032.

344 Harshyne, L A, S C Watkins, A Gambotto, and S M Barratt-Boyes. 2001. “Dendritic  
345 Cells Acquire Antigens from Live Cells for Cross-Presentation to CTL.” *Journal of*  
346 *Immunology (Baltimore, Md. : 1950)* 166 (6). American Association of  
347 Immunologists: 3717–23. doi:10.4049/JIMMUNOL.166.6.3717.

348 Harshyne, Larry A, Michael I Zimmer, Simon C Watkins, and Simon M Barratt-Boyes.  
349 2003. “A Role for Class A Scavenger Receptor in Dendritic Cell Nibbling from Live  
350 Cells.” *Journal of Immunology (Baltimore, Md. : 1950)* 170 (5). American  
351 Association of Immunologists: 2302–9. doi:10.4049/JIMMUNOL.170.5.2302.

352 Haso, Waleed, Daniel W. Lee, Nirali N. Shah, Maryalice Stetler-Stevenson, Constance  
353 M. Yuan, Ira H. Pastan, Dimiter S. Dimitrov, et al. 2013. “Anti-CD22-Chimeric  
354 Antigen Receptors Targeting B-Cell Precursor Acute Lymphoblastic Leukemia.”  
355 *Blood* 121 (7). American Society of Hematology: 1165–71. doi:10.1182/blood-2012-  
356 06-438002.

357 Hui, Enfu, and Ronald D Vale. 2014. “In Vitro Membrane Reconstitution of the T-Cell  
358 Receptor Proximal Signaling Network.” *Nature Structural & Molecular Biology* 21  
359 (2): 133–42. doi:10.1038/nsmb.2762.

360 Jadus, MR R, MC MR C R Irwin, MC MR C R Irwin, RD D Horansky, S Sekhon, KA a  
361 Pepper, DB B Kohn, and HT T Wepsic. 1996. “Macrophages Can Recognize and  
362 Kill Tumor Cells Bearing the Membrane Isoform of Macrophage Colony-Stimulating  
363 Factor.” *Blood* 87 (12): 5232–41.  
364 <http://www.bloodjournal.org/content/87/12/5232.long?sso-checked=true>.

365 Jaiswal, Siddhartha, Catriona H.M. Jamieson, Wendy W. Pang, Christopher Y. Park,  
366 Mark P. Chao, Ravindra Majeti, David Traver, Nico van Rooijen, and Irving L.  
367 Weissman. 2009. "CD47 Is Upregulated on Circulating Hematopoietic Stem Cells  
368 and Leukemia Cells to Avoid Phagocytosis." *Cell* 138 (2): 271–85.  
369 doi:10.1016/j.cell.2009.05.046.

370 James, John R., and Ronald D. Vale. 2012. "Biophysical Mechanism of T-Cell Receptor  
371 Triggering in a Reconstituted System." *Nature* 487 (7405): 64–69.  
372 doi:10.1038/nature11220.

373 Joly, Etienne, and Denis Hudrisier. 2003. "What Is Trogocytosis and What Is Its  
374 Purpose?" *Nature Immunology* 4 (9). Nature Publishing Group: 815–815.  
375 doi:10.1038/ni0903-815.

376 Kao, Gautam, Cheng Chen Huang, Edward M. Hedgecock, David H. Hall, and William  
377 G. Wadsworth. 2006. "The Role of the Laminin ?? Subunit in Laminin Heterotrimer  
378 Assembly and Basement Membrane Function and Development in *C. Elegans*."  
379 *Developmental Biology* 290 (1): 211–19. doi:10.1016/j.ydbio.2005.11.026.

380 Kochenderfer, James N., Steven A. Feldman, Yangbing Zhao, Hui Xu, Mary A. Black,  
381 Richard A. Morgan, Wyndham H. Wilson, and Steven A. Rosenberg. 2009.  
382 "Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen  
383 Receptor." *Journal of Immunotherapy* 32 (7). NIH Public Access: 689–702.  
384 doi:10.1097/CJI.0b013e3181ac6138.

385 Lacerna, Leocadio V., G.W. Stevenson, and Henry C. Stevenson. 1988. "Adoptive  
386 Cancer Immunotherapy Utilizing Lymphokine Activated Killer Cells and Gamma  
387 Interferon Activated Killer Monocytes." *Pharmacology & Therapeutics* 38 (3).  
388 Pergamon: 453–65. doi:10.1016/0163-7258(88)90014-9.

389 Lee, Simon, Saul Kivimäe, Aaron Dolor, and Francis C. Szoka. 2016. "Macrophage-  
390 Based Cell Therapies: The Long and Winding Road." *Journal of Controlled Release*  
391 240 (October). Elsevier: 527–40. doi:10.1016/J.JCONREL.2016.07.018.

392 Lim, Wendell A., Carl H. June, J. Huang, R.J. Hodes, S.A. Rosenberg, P.F. Robbins, K.  
393 McGary, et al. 2017. "The Principles of Engineering Immune Cells to Treat Cancer."  
394 *Cell* 168 (4). Elsevier: 724–40. doi:10.1016/j.cell.2017.01.016.

395 Liu, Xiaojuan, Yang Pu, Kyle Cron, Liufu Deng, Justin Kline, William A Frazier, Hairong  
396 Xu, Hua Peng, Yang-Xin Fu, and Meng Michelle Xu. 2015. "CD47 Blockade  
397 Triggers T Cell–mediated Destruction of Immunogenic Tumors." *Nature Medicine*  
398 21 (10). Nature Publishing Group, a division of Macmillan Publishers Limited. All  
399 Rights Reserved.: 1209–15. doi:10.1038/nm.3931.

400 Majeti, Ravindra, Mark P. Chao, Ash A. Alizadeh, Wendy W. Pang, Siddhartha Jaiswal,  
401 Kenneth D. Gibbs, Nico van Rooijen, and Irving L. Weissman. 2009. "CD47 Is an  
402 Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute  
403 Myeloid Leukemia Stem Cells." *Cell* 138 (2): 286–99.  
404 doi:10.1016/j.cell.2009.05.045.

405 Mayordomo, J I, T Zorina, W J Storkus, L Zitvogel, C Celluzzi, L D Falo, C J Melief, S T  
406 Ildstad, W M Kast, and A B Deleo. 1995. "Bone Marrow-Derived Dendritic Cells  
407 Pulsed with Synthetic Tumour Peptides Elicit Protective and Therapeutic  
408 Antitumour Immunity." *Nature Medicine* 1 (12): 1297–1302.  
409 <http://www.ncbi.nlm.nih.gov/pubmed/7489412>.

410 Penberthy, Kristen K., and Kodi S. Ravichandran. 2016. "Apoptotic Cell Recognition  
411 Receptors and Scavenger Receptors." *Immunological Reviews* 269 (1): 44–59.  
412 doi:10.1111/imr.12376.

413 Ralston, Katherine S, Michael D Solga, Nicole M Mackey-Lawrence, Alok Bhattacharya,  
414 and William A Petri Jr. 2014. "Trogoctosis by *Entamoeba Histolytica* Contributes to  
415 Cell Killing and Tissue Invasion." *Nature* 508. doi:10.1038/nature13242.

416 Roberts, Edward W., Miranda L. Broz, Mikhail Binnewies, Mark B. Headley, Amanda E.  
417 Nelson, Denise M. Wolf, Tsuneyasu Kaisho, Dusan Bogunovic, Nina Bhardwaj, and  
418 Matthew F. Krummel. 2016. "Critical Role for CD103+/CD141+ Dendritic Cells  
419 Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in

420 Melanoma.” *Cancer Cell* 30 (2). Cell Press: 324–36.  
421 doi:10.1016/J.CCELL.2016.06.003.

422 Schlam, Daniel, Richard D. Bagshaw, Spencer A. Freeman, Richard F. Collins, Tony  
423 Pawson, Gregory D. Fairn, and Sergio Grinstein. 2015. “Phosphoinositide 3-Kinase  
424 Enables Phagocytosis of Large Particles by Terminating Actin Assembly through  
425 Rac/Cdc42 GTPase-Activating Proteins.” *Nature Communications* 6 (October).  
426 Nature Publishing Group: 8623. doi:10.1038/ncomms9623.

427 Tseng, Diane, J.-P. Jens-Peter Volkmer, Stephen B. Willingham, Humberto Contreras-  
428 Trujillo, John W. Fathman, Nathaniel B. Fernhoff, Jun Seita, et al. 2013. “Anti-CD47  
429 Antibody-Mediated Phagocytosis of Cancer by Macrophages Primes an Effective  
430 Antitumor T-Cell Response.” *Proceedings of the National Academy of Sciences*  
431 110 (27): 11103–8. doi:10.1073/pnas.1305569110.

432 Weischenfeldt, Joachim, and Bo Porse. 2008. “Bone Marrow-Derived Macrophages  
433 (BMM): Isolation and Applications.” *CSH Protocols* 2008 (12). Cold Spring Harbor  
434 Laboratory Press: pdb.prot5080. doi:10.1101/PDB.PROT5080.

435 Xiao, Xiaodong, Mitchell Ho, Zhongyu Zhu, Ira Pastan, and Dimiter S. Dimitrov. 2009.  
436 “Identification and Characterization of Fully Human Anti-CD22 Monoclonal  
437 Antibodies.” *mAbs* 1 (3). Taylor & Francis: 297–303. doi:10.4161/mabs.1.3.8113.

438

439

440 **Figure legends**

441

442 **Figure 1: Identification of intracellular signaling region for CAR-P**

443 (A) Schematics show the structure of CAR-P constructs. An  $\alpha$ CD19 (purple) or  $\alpha$ CD22  
444 (blue, center) scFv directs CAR specificity. Intracellular signaling domains from Megf10  
445 or the indicated engulfment receptor (green) activate engulfment. CAR-P<sup>GFP</sup> contains  
446 only GFP and no intracellular signaling domains (right). All constructs include a  
447 transmembrane domain from CD8 and a C-terminal GFP. (B) J774A.1 macrophages  
448 expressing  $\alpha$ CD19 CAR-P with the indicated intracellular signaling domain (green)  
449 engulf 5  $\mu$ m silica beads covered with a supported lipid bilayer containing His-tagged  
450 CD19 extracellular domain. The beads were visualized with atto390-labeled lipid  
451 incorporated into the supported lipid bilayer (magenta). Cells infected with the cell  
452 membrane marker, mCherry-CAAX, were used as a control (no CAR, top left). To the  
453 right of each image is a histogram depicting the frequency of cells engulfing the  
454 indicated number of beads. The average number of beads eaten per cell is quantified in  
455 (C). (D) Bone marrow derived macrophages were infected with CAR-P<sup>FcRy</sup> or GFP-  
456 CAAX (green, left and center top; grey, center bottom) and incubated with CD19 beads  
457 (magenta) for 45 minutes. Images show an x-y plane through the center of the engulfed  
458 beads (left), or a cross section (center) of the z plane indicated in the inset panel (white  
459 line). The histogram depicts the number of cells engulfing the indicated number of  
460 beads. The scale bar indicates 5  $\mu$ m and n=78-163 cells per condition, collected during  
461 three separate experiments. Error bars denote 95% confidence intervals and \*\*\*  
462 indicates  $p < 0.0001$  compared to mCherry-CAAX control by Kruskal-Wallis test with  
463 Dunn's multiple comparison correction

464

465 **Figure 2: CAR-P expression drives specific engulfment of diverse beads**

466 (A) Macrophages infected with the  $\alpha$ CD19 (purple) or  $\alpha$ CD22 (blue) CAR-P<sup>Megf10</sup> or  
467 mCherry-CAAX control were fed 5  $\mu$ m beads ligated with either CD19 (left) or CD22  
468 (right). Engulfment is quantified as the mean beads eaten per cell. The fraction of  
469 phagocytic cells is as follows: 31/144 GFP-CAAX cells engulfed CD19 beads, 87/149  
470  $\alpha$ CD19 CAR-P<sup>Megf10</sup> engulfed CD19 beads, 20/142  $\alpha$ CD22 CAR-P<sup>Megf10</sup> engulfed CD19

471 beads, 28/140 GFP-CAAX cells engulfed CD22 beads, 18/151  $\alpha$ CD19 CAR-P<sup>Megf10</sup>  
472 engulfed CD22 beads, 103/148  $\alpha$ CD22 CAR-P<sup>Megf10</sup> engulfed CD22 beads (pooled data  
473 was collected during three separate experiments). Error bars denote 95% confidence  
474 intervals and \*\*\* indicates  $p < 0.0001$  compared to mCherry-CAAX control by Kruskal-  
475 Wallis test with Dunn's multiple comparison correction. (B) J774A.1 macrophages  
476 expressing the  $\alpha$ CD19 CAR-P<sup>Megf10</sup> (green) were fed beads of various sizes (magenta,  
477 diameter of bead indicated below image). The beads were covered in a supported lipid  
478 bilayer ligated to His-tagged CD19 extracellular domain and the number of beads  
479 engulfed per cell is reported below each image (magenta bars indicate CAR-P<sup>Megf10</sup>  
480 macrophages and pink bars indicate CAR-P<sup>GFP</sup>). The  $\alpha$ CD19 CAR-P<sup>Megf10</sup> macrophages  
481 were also incubated with 10  $\mu$ m beads coated in phosphatidylserine (PS) and ICAM-1  
482 (blue bar in graph, 51/390 cells engulfed a bead). The fraction of cells engulfing a CD19  
483 bead is as follows: 135/169 CAR-P<sup>Megf10</sup> and 134/187 CAR-P<sup>GFP</sup> cells engulfed 2.5  $\mu$ m  
484 bead, 126/395 CAR-P<sup>Megf10</sup> and 112/499 CAR-P<sup>GFP</sup> cells engulfed a 5  $\mu$ m bead, 48/377  
485 CAR-P<sup>Megf10</sup> and 21/378 CAR-P<sup>GFP</sup> cells engulfed a 10  $\mu$ m bead, 120/706 CAR-P<sup>Megf10</sup>  
486 and 45/675 CAR-P<sup>GFP</sup> cells engulfed a 15  $\mu$ m bead, 194/760 CAR-P<sup>Megf10</sup> and 23/587  
487 CAR-P<sup>GFP</sup> cells engulfed a 20  $\mu$ m bead (data is pooled from at least three separate  
488 experiments). Error bars denote 95% confidence intervals of the mean. \*\*\* indicates  
489  $p < 0.0001$  respectively by Mann-Whitney test. All scale bars represent 5  $\mu$ m.

490

### 491 **Figure 3: A phosphorylated ITAM at the cell-target synapse drives engulfment**

492 (A) Macrophages expressing  $\alpha$ CD19 CAR-P<sup>Megf10</sup> (green, top) or  $\alpha$ CD19 CAR-P<sup>GFP</sup>  
493 were incubated with CD19-ligated beads (position indicated with dotted line), fixed and  
494 stained for phosphotyrosine (magenta, top; greyscale, bottom). The fold enrichment of  
495 phosphotyrosine at the cell-bead synapse compared to the cell cortex is graphed on the  
496 right ( $n \geq 11$ ; each dot represents one cell-bead synapse; lines represent the mean  $\pm$  one  
497 standard deviation). (B) Schematic shows the structure of CAR-P constructs in the plot  
498 at right. An  $\alpha$ CD19 (purple) scFv directs CAR specificity. The intracellular signaling  
499 domains from CD3 $\zeta$  activate engulfment. On the right is a histogram depicting the  
500 fraction of macrophages engulfing the indicated number of CD19-coated beads. (C)  
501 Comparison showing the average number of beads eaten per cell in J774A.1

502 macrophages expressing  $\alpha$ CD19 CAR-Ps with the indicated intracellular signaling  
503 domain. 5  $\mu$ m silica beads covered with a supported lipid bilayer containing His-tagged  
504 CD19 extracellular domain were used as an engulfment target (n=156-167 cells per  
505 condition collected during three separate experiments). Error bars denote 95%  
506 confidence intervals and \*\*\* indicates  $p < 0.0001$  compared to CAR-P<sup>GFP</sup> control by  
507 Kruskal-Wallis test with Dunn's multiple comparison in correction. (D) Model of the  
508 liposome-based fluorescence quenching assay used to determine affinity between the  
509 Syk tSH2 domains and the receptor tails of CD3 $\zeta$  and FcR $\gamma$ , two intracellular signaling  
510 domains that promote engulfment. Binding between the Syk tSH2 reporter (Syk tSH2),  
511 green, and a receptor tail, purple, was detected by rhodamine quenching of BG505 dye  
512 on the reporter (see Methods). K<sub>d</sub> was determined by assessing mean fluorescence  
513 quenching for the last 20 timepoints collected ~45 min after ATP addition over a  
514 receptor titration from 0 to 500 nM. Each point represents the mean  $\pm$  SD from 3  
515 independent experiments. K<sub>d</sub>  $\pm$  SE was calculated by nonlinear fit assuming one site  
516 specific binding.

517

#### 518 **Figure 4: CAR-P promotes trogocytosis and whole cell eating**

519 (A) J774A.1 macrophages expressing the  $\alpha$ CD19 CAR-P<sup>Megf10</sup> (top panel, green in  
520 merge, left; greyscale, center) engulf pieces of CD19+ Raji B cells (labeled with  
521 mCherry-CAAX; magenta in merge, left; greyscale, right). The corresponding control  
522  $\alpha$ CD19 CAR-P<sup>GFP</sup>-infected cells are shown below. Arrows point to pieces of ingested  
523 Raji B cell. The proportion of CAR-P expressing macrophages internalizing one or more  
524 bite within 90 min is quantified on the right. Bites are defined as a fully internalized  
525 mCherry-positive vesicle  $>1 \mu$ m in diameter; n=46 CAR-P<sup>Megf10</sup> macrophages, n=39  
526 CAR-P<sup>FcR $\gamma$</sup>  macrophages and 102 CAR-P<sup>GFP</sup> macrophages acquired during three  
527 separate experiments. (B) Time course of a J774A.1 macrophage expressing CAR-  
528 P<sup>FcR $\gamma$</sup>  (green) internalizing a whole Raji B cell labeled with mCherry-CAAX (magenta).  
529 These images correspond to frames from Figure 4- Video 2. (C) Schematic shows the  
530 structure of CAR-P<sup>tandem</sup> construct, combining the intracellular signaling domain from  
531 FcR $\gamma$  and the p85 recruitment domain from CD19. (D) Time course of a J774A.1  
532 macrophage expressing CAR-P<sup>tandem</sup> (green) internalizing a whole Raji B cell labeled

533 with mCherry-CAAX (magenta). These images correspond to frames from Figure 4-  
534 Video 3. (E) Macrophages and Raji B cells were incubated together at a 1:2  
535 macrophage:Raji ratio, and the number of whole Raji B cells eaten per 100  
536 macrophages during 4-8 hr of imaging is graphed. Graph depicts pooled data from 4  
537 independent experiments;  $n = 921$  CAR-P<sup>GFP</sup>,  $n = 762$  CAR-P<sup>FcRγ</sup>,  $n = 638$  CAR-P<sup>Pi3K</sup>,  $n$   
538  $= 555$  CAR-P<sup>tandem</sup> cells. Sample sizes were selected for their ability to detect a 5%  
539 difference between samples with 95% confidence. (F) 10,000 macrophages and 20,000  
540 Raji B cells were incubated together for 44 hr. The number of Rajis was then quantified  
541 by FACS. 2-3 technical replicates were acquired each day on three separate days. The  
542 number of Rajis in each replicate was normalized to the average number present in the  
543 GFP-CAAX macrophage wells on that day. \* indicates  $p < 0.01$ , \*\*\* indicates  $p < 0.0001$  by  
544 two-tailed Fisher Exact Test (a and e) or by Ordinary one way ANOVA with Dunnet's  
545 correction for multiple comparisons (f); error bars denote 95% confidence intervals.

546

547

548

549

550

551 **Figure Supplement Legends**

552

553 **Figure 1- figure supplement 1: Expression level of CAR-P constructs in**  
554 **macrophages**

555 Images of macrophages infected with various  $\alpha$ CD19 CAR-P<sup>GFP</sup> constructs were  
556 acquired with identical acquisition settings and scaling to depict differences in  
557 expression levels. Fluorescent intensity at the cell cortex of 20 representative  $\alpha$ CD19  
558 CAR-P<sup>GFP</sup>-infected macrophages was quantified using the mean intensity of a 2 pixel  
559 width linescan at the cell membrane, minus the mean intensity of a linescan  
560 immediately adjacent to the cell. The images are the same cells included in Figure 1B  
561 and fluorescent intensity was measured from the same macrophages assayed in Figure  
562 1C. The dashed red line indicates the position of a bead in contact with the CAR-P<sup>GFP</sup>  
563 macrophage. The scale bar indicates 5  $\mu$ m.

564

565 **Figure 3- figure supplement 1: F-actin is enriched at the cell-target synapse**

566 Phalloidin staining (magenta overlaid with brightfield and DAPI, left; heatmap, right) of  
567 F-actin in a CAR-P<sup>FcR $\gamma$</sup>  expressing macrophage shows a 2.3 fold enrichment at the cell-  
568 bead synapse (standard deviation of 1.2). The graph depicts actin enrichment at 30 cell-  
569 bead synapses collected on three separate days. Each dot represents a cell-bead  
570 synapse. The box plot indicates the interquartile range. The cell is in contact with a  
571 second bead, but this site of contact has not initiated cup formation and no actin  
572 enrichment.

573

574 **Figure 4- figure supplement 1: CAR-P localizes with pTyr at synapse with Raji B**  
575 **cell**

576 Phosphotyrosine staining (teal) of macrophages expressing CAR-P<sup>Megf10</sup> (green) in  
577 contact with Raji B cells (cell membrane visualized with mCherry-CAAX, magenta).  
578 Below, the enrichment at the synapse is quantified as the mean intensity of a 5 pixel  
579 width linescan at the synapse divided by the mean intensity at the adjacent cell cortex  
580 for at least 11 sites of contact. Each dot represents one cell-cell synapse, lines

581 represent the mean  $\pm$  one standard deviation, and the graph is the pooled results o  
582 three biological replicates. The scale bar indicates 5  $\mu$ m.

583

584 **Figure 4- figure supplement 2: NIH 3T3 cells internalize Raji B cell bites**

585 NIH 3T3 cells expressing the  $\alpha$ CD19 CAR-P<sup>Megf10</sup> (green in merge, left; greyscale,  
586 center) engulf pieces of CD19+ Raji B cells (labeled with mCherry-CAAX; magenta in  
587 merge, left; greyscale, right). The control  $\alpha$ CD19 CAR-P<sup>GFP</sup>-infected 3T3s are shown  
588 below. Arrows point to pieces of ingested Raji B cell. The proportion of cells taking at  
589 least one bite after 90 min co-incubation is graphed on the left (graphs show the pooled  
590 data of three separate experiments; n=111 CAR-P<sup>Megf10</sup> 3T3 cells and 121 CAR-P<sup>GFP</sup>  
591 3T3; \*\*\* indicates p<0.0001 by two-tailed Fisher Exact Test; error bars denote 95%  
592 confidence intervals). Bites are defined as a fully internalized piece of mCherry-labeled  
593 material >1  $\mu$ m in diameter.

594

595 **Figure 4- figure supplement 3: Opsonization by an anti-CD47 antibody enhances**

596 **whole cell internalization through CAR-P** Macrophages expressing CAR-P<sup>FcR $\gamma$</sup>  and  
597 Raji B cells were incubated together at a 1:2 macrophage:Raji ratio (20,000  
598 macrophages and 40,000 Rajis) without antibody addition (No ab) or in the presence of  
599 anti-CD19 or anti-CD47 antibodies as indicated. The number of whole Raji B cells eaten  
600 per 100 macrophages during 4-8 hr of imaging is graphed. Graph depicts pooled data  
601 from 3 independent experiments; n = 232 with no antibody, n = 257 with anti-CD19  
602 antibody, n = 347 with anti-CD47 antibody; \* indicates p<0.05 by two-tailed Fisher  
603 Exact test.

604

605 **Figure 4- figure supplement 4: CAR-P promotes internalization of cancer antigen**

606 (A) Schematic of antigen internalization and cross-presentation assay. CAR-P  
607 expressing Bone Marrow Derived Dendritic Cells (BMDC) were differentiated using GM-  
608 CS. CAR-P BMDC were incubated with Raji B cells expressing soluble ovalbumin  
609 (OVA). DC with OVA bites (internalized antigen) were then incubated with OTI T cells  
610 (OVA specific CD8+ T cells) and OTI proliferation assessed as a measure of T cell  
611 stimulation. Results from each step of this assay are shown in sequence in (B), (C), and

612 (D). (B) Ovalbumin staining (magenta) in Raji B cells infected with mCherry-CAAX-p2a-  
613 Ovalbumin lentivirus (OVA) and uninfected controls (uninfected) shows robust OVA  
614 expression in infected cells. At right the intracellular OVA signal is plotted as corrected  
615 total cell fluorescence (CTCF) for the ovalbumin channel. Each dot represents the  
616 CTCF of one cell; n=26 cells OVA, n=33 cells (uninfected); lines represent the mean  $\pm$   
617 one standard deviation, and the graph is the pooled results of three biological replicates.  
618 The scale bar indicates 5  $\mu$ m. (C) Bone marrow-derived dendritic cells expressing the  
619 CAR-P<sup>FcRy</sup> (top panel, green in merge, left; greyscale, center) engulf pieces of CD19+  
620 Raji B cells (labeled with mCherry-CAAX; magenta in merge, left; greyscale, right). The  
621 control  $\alpha$ CD19 CAR-P<sup>GFP</sup>-infected dendritic cells are shown below. Arrows point to  
622 pieces of ingested Raji B cell. The proportion of cells taking at least one bite after 90  
623 min co-incubation is graphed on the right of images. Graphs show the pooled data of  
624 two separate experiments; n=28 CAR-P<sup>FcRy</sup> dendritic cells and n=33 CAR-P<sup>GFP</sup> dendritic  
625 cells; \*\*\* indicates p<0.0001 by two-tailed Fisher Exact Test; error bars denote 95%  
626 confidence intervals. Bites are defined as a fully internalized piece of mCherry-labeled  
627 material >1  $\mu$ m in diameter. (D) OTI T cell proliferation after 72hr incubation with CAR-P  
628 transduced CD11c+ dendritic cells. +/- RAJI below the x-axis indicates whether Raji-  
629 OVA B cells were added to CAR-P transduced dendritic cells prior to OTI addition. To  
630 measure proliferation, T cells were uniformly stained with eFluor670 dye on day 0, and  
631 proliferation was measured by dilution of the cell-bound dye. Graphs show the mean  $\pm$   
632 SD of three independent biological replicates. Data points are values for individual wells  
633 of differentiated CD11c+ dendritic cells. Boxed data indicate the mean % T cells dividing  
634 when dendritic cells were pulsed with SL8 (OVA) peptide, which directly binds to MHC  
635 without undergoing cross presentation. If dendritic cell differentiation was successful,  
636 the pulsed dendritic cells should be capable of inducing robust OTI proliferation. Sample  
637 sizes were selected to match previous studies that were able to detect robust T cell  
638 stimulation (Roberts et al. 2016).  
639  
640

641 **Video legends**

642

643 **Figure 1- Video 1: CAR-P<sup>Megf10</sup> macrophage engulfs silica beads**

644 A macrophage infected with  $\alpha$ CD19 CAR-P<sup>Megf10</sup> (green) engulfs 5  $\mu$ m silica beads  
645 coated in a supported lipid bilayer (labeled with atto647, magenta) and ligated to his-  
646 tagged CD19 extracellular domain. The field of view is 43 x 43  $\mu$ m. The movie is a  
647 maximum intensity projection of 17 z-planes acquired at 0.5  $\mu$ m intervals. Z-stacks were  
648 acquired every 30 sec for 30 min and time is indicated in the bottom right.

649

650 **Figure 4- Video 1: CAR-P<sup>Megf10</sup> macrophage engulfs bites of a Raji B cell**

651 A macrophage infected with  $\alpha$ CD19 CAR-P<sup>Megf10</sup> (green) engages with a Raji B cell  
652 (labeled with mCherry-CAAX). The field of view is 43 x 43  $\mu$ m. The movie is a maximum  
653 intensity projection of 7 z-planes acquired at 1  $\mu$ m intervals. Images were acquired  
654 every 20 sec for 30 min and time is indicated in the bottom right.

655

656 **Figure 4- Video 2: CAR-P<sup>FcR $\gamma$</sup>  macrophage engulfs a Raji B cell.**

657 A macrophage infected with  $\alpha$ CD19 CAR-P<sup>FcR $\gamma$</sup>  (green) engages with a Raji B cell  
658 (labeled with mCherry-CAAX). The field of view is 53x53  $\mu$ m. Images were acquired  
659 every 5 min. Time is indicated in the bottom right.

660

661 **Figure 4- Video 3: CAR-P<sup>tandem</sup> macrophage engulfs a Raji B cell.**

662 A macrophage infected with  $\alpha$ CD19 CAR-P<sup>tandem</sup> (green) engages with a Raji B cell  
663 (labeled with mCherry-CAAX). The field of view is 53x53  $\mu$ m. Images were acquired  
664 every 5 min. Time is indicated in the bottom right.

665

666

667 **Materials and Methods**

668

669 **Constructs and Antibodies**

670 Detailed information for all constructs can be found in Supplemental Excel File 1,  
671 “Constructs” tab. This file includes the following information for all receptors developed  
672 in this study: signal peptide, extracellular antibody fragment, stalk/transmembrane  
673 domain, and cytosolic tail including appropriate accession numbers. Antibodies used in  
674 this study are described in Supplemental Excel File 1, “Antibodies” tab.

675

676 **Cell culture**

677 J774A.1 macrophages and NIH 3T3 fibroblasts were obtained from the UCSF cell  
678 culture facility and cultured in DMEM (Gibco, Catalog #11965-092) supplemented with 1  
679 x Pen-Strep-Glutamine (Corning, Catalog #30-009-CI) and 10% fetal bovine serum  
680 (FBS) (Atlanta Biologicals, Catalog #S11150H). Raji B cells were obtained from J. Blau  
681 (McManus lab, UCSF) and cultured in RPMI (Gibco, Catalog #11875-093)  
682 supplemented with 1 x Pen-Strep-Glutamine (Corning, Catalog #30-009-CI), 10% FBS  
683 (Atlanta Biologicals, Catalog #S11150H), 10mM HEPES (Gibco, Catalog #1530080),  
684 and 5  $\mu$ M 2-Mercaptoethanol (Sigma, Catalog #M6250-100mL). All cell lines used in this  
685 study were tested for Mycoplasma at least once per month using the Lonza MycoAlert  
686 Detection Kit (Lonza, Catalog# LT07-318) and control set (Lonza, Catalog #LT07-518).

687

688 **Lentivirus production and infection**

689 Lentiviral infection was used to stably express CAR-P constructs in all cell types.  
690 Lentivirus was produced by HEK293T cells transfected with pMD2.G (a gift from Didier  
691 Trono, Addgene plasmid # 12259 containing the VSV-G envelope protein), pCMV-  
692 dR8.91 (since replaced by 2<sup>nd</sup> generation compatible pCMV-dR8.2, Addgene plasmid  
693 #8455), and a lentiviral backbone vector containing the construct of interest (derived  
694 from pHRSIN-CSGW) using lipofectamine LTX (Invitrogen, Catalog # 15338-100). The  
695 media on the HEK293T cells was replaced with fresh media 8-16 hours post  
696 transfection to remove transfection reagent. At 50-72 hr post-transfection, the lentiviral  
697 media was filtered with a 0.45  $\mu$ m filter and concentrated by centrifugation at 8,000 x g

698 for 4 hr or overnight. The concentrated supernatant was applied directly to  $\sim 0.5 \times 10^6$   
699 NIH 3T3 cells in 2 ml of fresh media. For J77A4.1 macrophages and Raji B cells, the  
700 concentrated supernatant was mixed with 2 mls of media and 2  $\mu$ g lipofectamine  
701 (Invitrogen, Catalog # 18324-012) and added to the cells. The cells were spun at 2,200  
702 x g for 45 min at 37°C. Cells were analyzed a minimum of 72 hr later.

703

#### 704 **Preparation of CD19 and CD22 5 $\mu$ m silica beads**

705 Chloroform-suspended lipids were mixed in the following molar ratio using clean  
706 glasstight Hamilton syringes (Hamilton, Catalog #8 1100): 97% POPC (Avanti, Catalog  
707 # 850457), 2% Ni<sup>2+</sup>-DGS-NTA (Avanti, Catalog # 790404), 0.5% PEG5000-PE (Avanti,  
708 Catalog # 880230, and 0.5% atto390-DOPE (ATTO-TEC GmbH, Catalog # AD 390-  
709 161). Lipid mixes were dried under argon and desiccated overnight under foil. Dried  
710 lipids were resuspended in 1 ml tissue-culture grade PBS, pH7.2 (Gibco, Catalog #  
711 20012050), and stored under argon gas. Small unilamellar vesicles were formed by 5  
712 freeze-thaw cycles followed by 2 x 5 min of bath sonication (Bioruptor Pico, Diagenode),  
713 and cleared by ultracentrifugation (TLA120.1 rotor, 35,000 rpm / 53,227 x g, 35 minutes,  
714 4°C) or by 33 freeze thaw cycles. Lipid mixes were used immediately for form bilayers  
715 or shock frozen in liquid nitrogen and stored under argon at -80°C. To form bilayers on  
716 silica beads,  $6 \times 10^8$  5  $\mu$ m silica microspheres (10% solids, Bangs Labs, Catalog #  
717 SS05N) were washed 2x in water, and 2x in PBS by sequential suspension in water and  
718 spinning at 800 rcf, followed by decanting. Cleaned beads were resuspended in 150  $\mu$ l  
719 tissue-culture grade PBS, pH7.2 (Gibco, Catalog # 20012050) and briefly vortexed. 30  
720  $\mu$ l cleared SUVs prepared as above as a 10 mM stock were added to bead suspension  
721 for a 2 mM final SUV concentration. Beads were vortexed for 10 sec, covered in foil,  
722 and rotated for 30 min at room temperature to form bilayers. Bilayer-coated beads were  
723 washed 3x in PBS by sequential centrifugation at 800 rcf and decanting. Beads were  
724 resuspended in PBS + 0.1% w/v BSA for blocking for 15 min rotating at room  
725 temperature under foil. 10 nM final concentration of CD19<sub>his8</sub> (Sino Biological, Catalog #  
726 11880H08H50) or CD22<sub>his8</sub> (Sino Biological, Catalog # 11958H08H50) protein were  
727 added to blocked beads and proteins were allowed to bind during a 45 min incubation  
728 rotating under foil at room temperature. Beads were washed 3x in PBS + 0.1% w/v BSA

729 by sequential centrifugation at 300 rcf and decanting. Beads were resuspended in 120  
730 ml PBS + 0.1% w/v BSA.

731

### 732 **Preparation of CD19 silica beads over a range of diameters**

733 Prior building bilayers on Silica beads ranging from 2.5  $\mu\text{m}$ -20  $\mu\text{m}$  in diameter  
734 (Microspheres-Nanospheres, Catalog# C-SIO-2.5, 5, 10, 15, 20), beads were RCA  
735 cleaned as follows: beads were pelleted at 2,000xg in low retention tubes (Eppendorf,  
736 Catalog #022431081) and resuspended in acetone. Resuspended beads were  
737 sonicated for 60 min in a bath sonicator. Rinse and sonication were repeated in ethanol.  
738 Finally, rinse and sonication were repeated in water. Beads were then washed 2x in  
739 water to remove all traces of ethanol and left in a small volume after decanting. All  
740 further steps were performed in a 70-80°C water bath prepared in a fume hood. Proper  
741 Personal Protective Equipment (PPE) was worn throughout the RCA cleaning protocol.  
742 Washed beads were added to 3 ml of hot 1.5 M KOH in a clean glass vial suspended in  
743 the water bath described above. 1 ml 30% H<sub>2</sub>O<sub>2</sub> to bead solution and allowed to react  
744 for 10 minutes. Washed beads were cooled on ice, pelleted at 2,000xg and rinsed 5x in  
745 ultrapure water. Used cleaning solution was saved for disposal by Environmental Health  
746 & Safety (EH&S). Cleaned beads were resuspended in 240  $\mu\text{l}$  tissue-culture grade PBS,  
747 pH7.2 (Gibco, Catalog # 20012050) and briefly vortexed. The lipid mix used in this  
748 assay differed slightly from above. Here a mix of 93.5% POPC (Avanti, Catalog #  
749 850457), 5% Ni<sup>2+</sup>-DGS-NTA (Avanti, Catalog # 790404), 1% PEG5000-PE (Avanti,  
750 Catalog # 880230, and 0.5% atto390-DOPE (ATTO-TEC GmbH, Catalog # AD 390-161).  
751 Bilayers were built and proteins coupled as described above. The concentration of  
752 CD19 was scaled appropriately to account for the increased surface area of the larger  
753 beads.

754

### 755 **Bead engulfment assay**

756 12 to 16 hr prior to imaging, 2.5x10<sup>4</sup> J774A.1 macrophages expressing the appropriate  
757 CAR-P or control construct were plated in a 96-well glass bottom MatriPlate (Brooks,  
758 Catalog # MGB096-1-2-LG-L). To assess engulfment, 0.5 x 10<sup>6</sup> CD19 or CD22-ligated  
759 beads were added to each well. Engulfment was allowed to proceed for 45 min at 37°C

760 incubator with CO<sub>2</sub>. Cells were then imaged as described below.

761

762 **Bites assay – J774A.1 macrophages, dendritic cells and NIH 3T3 fibroblasts**

763 On the day of imaging 0.5 x 10<sup>6</sup> NIH 3T3 fibroblasts, dendritic cells or macrophages and  
764 1.5 million Raji B cells were combined in a 1.5 ml eppendorf tube and pelleted by  
765 centrifugation (800 rpm / 68 x g) for 5 min at room temperature. Culture media was  
766 decanted to ~100 µl volume and cells were gently resuspended, and allowed to interact  
767 in the small volume for 60 min in a 37°C incubator with CO<sub>2</sub>. After incubation cells and  
768 beads were diluted to a final volume of 1000 µl and 300 µl of this co-culture plated for  
769 imaging in a 96-well glass bottom MatriPlate (Brooks, Catalog # MGB096-1-2-LG-L),  
770 and imaged as described below.

771

772 **Eating assay read by FACS – J774A.1 macrophages and Raji B cells**

773 20,000 J774A.1 macrophages were plated into 96-well glass bottom MatriPlate (Brooks,  
774 Catalog # MGB096-1-2-LG-L) in a final volume of 300 µl complete DMEM (Gibco,  
775 Catalog #11965-092) supplemented with 1 x Pen-Strep-Glutamine (Corning, Catalog  
776 #30-009-CI) and 10% fetal bovine serum (FBS) (Atlanta Biologicals, Catalog  
777 #S11150H). 52 hrs prior to reading the assay macrophages were stimulated with 500  
778 ng/ml LPS (Sigma, Catalog # L4516). 44 hrs prior to imaging LPS was removed by  
779 three sequential gentle washes. After LPS removal 10,000 Rajis expressing mCherry-  
780 CAAX were added to the well containing stimulated macrophages. The co-culture was  
781 incubated for 44 hrs in a 37°C tissue culture incubator with 5% CO<sub>2</sub>. After 44 hrs, the  
782 remaining number of Raji B cells remaining was analyzed by FACS as follows: 10,000  
783 counting beads were added to the well immediately prior to reading and the cell-  
784 counting bead mixture was harvested by pipetting up and down 8x with a p200 pipet.  
785 The assay was read on an LSRII (BD Biosciences) and Rajis were identified by the  
786 presence of mCherry fluorescence.

787

788 **Primary cell transduction and differentiation**

789 Bone marrow derived macrophages (BMDMs) were produced as previously described  
790 (Weischenfeldt and Porse 2008), except that L-929 conditioned media was replaced

791 with purified 25 ng/ml M-CSF (Peprotech, Catalog # 315-02). The BMDMs were  
792 lentivirally infected with concentrated lentivirus after 5 days of differentiation.  
793 Differentiation was confirmed by F4/80 staining on day 7 and found to be >95% efficient  
794 for each replicate. Phagocytosis was measured on day 9 in imaging media lacking M-  
795 CSF.

796 To produce CAR-P expressing dendritic cells, bone marrow-derived hematopoietic stem  
797 cells were lentivirally infected immediately after harvest by spinning with concentrated  
798 lentivirus in GMCSF-containing media (IMDM supplemented with 10% FBS and PSG)  
799 on retronectin (Clontech, Catalog # T100A)-coated plates at 2,200 x g for 45 min at  
800 37°C. Dendritic cells were produced as previously described (Mayordomo et al. 1995)  
801 by culturing bone marrow cells for 8-11 days with GMCSF. IL-4 was added 2-3 days  
802 before use. Efficient differentiation into CD11c+ dendritic cells was verified by FACS,  
803 revealing  $\geq 95\%$  APC-CD11c+ cells (Biolegend, Catalog #N418).

804

#### 805 **Antigen cross-presentation assay**

806 The ability of CAR-P to stimulate OTI T cell proliferation was tested using the co-culture  
807 assay shown as a schematic in Figure S4A and described previously (Roberts et al.  
808 2016). 10,000 CAR-P transduced CD11c+ dendritic cells transduced and differentiated  
809 as above were plated in U bottom 96 well dishes (Falcon, Catalog #353077) and  
810 stimulated with 1ug/ml LPS. 12 hrs after LPS stimulation, 40,000 Raji B cells expressing  
811 soluble cytosolic ovalbumin (Raji B-OVA) were added to the culture. 24 hrs after Raji B-  
812 OVA cell addition, 50,000 OTI CD8+ T cells isolated from lymph nodes of OTI TCR  
813 transgenic mice using a CD8+ T cell purification kit (Stemcell, Catalog #19853) and  
814 labeled with e670 proliferation dye (Thermo, Catalog #65-0840-85) were added. 72hrs  
815 after OTI addition the percent of OTI cells divided was measured by eFluor670 signal  
816 using flow cytometry.

817

#### 818 **Confocal imaging**

819 All imaging in this study was performed using a spinning disk confocal microscope with  
820 environmental control (Nikon Ti-Eclipse inverted microscope with a Yokogawa spinning  
821 disk unit). For bead internalization assays, images were acquired using a 40x 0.95 N/A

822 air objective and unbiased live image acquisition was performed using the High Content  
823 Screening (HCS) Site Generator plugin in  $\mu$ Manager<sup>3</sup>. Other images were acquired  
824 using either a 100x 1.49 N/A oil immersion objective. All images were acquired using an  
825 Andor iXon EM-CCD camera. The open source  $\mu$ Manager software package was used  
826 to control the microscope and acquire all images<sup>3</sup>.

827

### 828 **Quantification of whole cell internalization**

829 20,000 J774A.1 macrophages were plated into 96-well glass bottom MatriPlate (Brooks,  
830 Catalog # MGB096-1-2-LG-L). Four hours prior to imaging, the macrophages were  
831 stimulated with 500 ng/ml LPS (Sigma, Catalog # L4516). Immediately prior to imaging  
832 the LPS-containing media was replaced with Fluobrite DMEM (ThermoFisher Scientific,  
833 Catalog # A1896701) containing 10% FBS. 40,000 Raji cells were added to the  
834 macrophages and the co-culture was imaged at 5 minute intervals for 12 hours. For the  
835 antibody experiments, macrophages were washed into DMEM minus phenol red  
836 (A14430-01) containing 10% FBS just prior to addition of 40,000 Raji cells. Where  
837 indicated antibody was added to a final concentration of 20  $\mu$ g/ml immediately after Raji  
838 cell addition and prior to imaging to limit antibody internalization. Because cells moved  
839 in and out of the field of view, we selected the cells present after 8 hours of imaging and  
840 quantified their B cell eating if they could be followed for four hours or more. Time-lapse  
841 analysis was essential to ensure that the B cell appeared viable prior to engulfment by  
842 the macrophage. Engulfment of B cells with an apoptotic morphology was not counted  
843 as a whole cell eating event.

844

### 845 **Quantification of bites internalization**

846 During live cell image acquisition GFP-positive J774A.1 macrophages or NIH 3T3 cells  
847 were selected by the presence of GFP signal. A full z-stack comprising the entire cell  
848 was captured using 1  $\mu$ m steps. All z sections were then manually inspected for  
849 internalized Raji B cell material. Cells containing one or more bites of fully internalized  
850 Raji B cell material  $>1 \mu$ m in diameter were scored as positive.

851

### 852 **Liposome FRET assay**

853 Experiments were carried out as previously described<sup>2</sup>. Briefly, proteins were purified  
854 using a bacterial expression system. All protein components (1 mg/ml BSA, 100 nM  
855 tSH2-Syk SNAP-505, 0 to 500 nM His10-CD3 $\zeta$  or His10-FcR $\gamma$  intracellular chain, and  
856 7.2 nM His10-Lck Y505F) were mixed into kinase buffer (50 mM HEPES-NaOH pH 6.8,  
857 150 mM NaCl, 10 mM MgCl<sub>2</sub>, and 1 mM TCEP). Liposomes prepared at the following  
858 molar ratios: 74.5 % POPC (Avanti, Catalog # 850457C), 10% DOGS-NTA (Nickel)  
859 (Avanti, Catalog # 790404C, 0.5% Rhodamine PE (Avanti, Catalog # 810150C), and  
860 15% DOPS (Avanti, Catalog # 840035C) were added and the mixture was incubated for  
861 40–60 min at room temperature, during which the SNAP-505 fluorescence was  
862 monitored at 8 s intervals with 504-nm excitation and 540-nm emission. 1 mM ATP was  
863 then injected to trigger Lck mediated phosphorylation of CD3 $\zeta$  or FcR $\gamma$ . Injection was  
864 followed by 5 s of automatic shaking of the plate, and the fluorescence was further  
865 monitored at 8 s intervals for at least 1 hr. Data were normalized by setting the average  
866 fluorescence value of the last 10 data points before ATP addition as 100% and  
867 background fluorescence as 0%. The final extent of fluorescence quenching (%  
868 fluorescence change) at each concentration of receptor was determined using the  
869 average of the last 20 data points after ensuring fully equilibrated binding. Nine  
870 reactions containing increasing concentrations of CD3 $\zeta$  and nine reactions containing  
871 increasing concentrations of FcR $\gamma$  were run in parallel. The final % fluorescence change  
872 was plotted against FcR $\gamma$  or CD3 $\zeta$  concentration. The apparent dissociation constants  
873 (K<sub>d</sub>) of tSH2-Syk to FcR $\gamma$  and CD3 $\zeta$  were calculated by fitting the data with Graphpad  
874 Prism 6.0, using the “one site specific binding” model.

875

### 876 **Protein expression, purification, and labeling**

877 The intracellular portion of the FcR  $\gamma$ -chain (aa 45-85, Human FcR $\gamma$ , Uniprot  
878 FCERG\_HUMAN) was cloned into a modified pET28a vector containing a His10  
879 upstream to the multiple cloning site using BamHI and EcoRI. The intracellular portion  
880 of CD3 $\zeta$  (aa 52–164, Human CD3 $\zeta$ , Uniprot CD3Z\_HUMAN) was also cloned into the  
881 His10 modified pET28a vector. A Lys-Cys-Lys-Lys sequence, originally present for  
882 fluorescent labeling, is also present between His10 and CD3 $\zeta$  in this construct. SNAP-  
883 tSH2Syk (aa 1-262) was cloned into a pGEX6 vector using BamHI and EcoRI. His10-

884 CD3 $\zeta$ , His<sub>10</sub>-FcR  $\gamma$ -chain, and GST-SNAP-tSH2Syk were bacterially expressed in BL21  
885 (DE3) RIPL strain of *Escherichia coli* as described previously<sup>2</sup>. His<sub>10</sub>-Lck Y505F was  
886 expressed in SF9 cells using the Bac-to-Bac baculovirus system as described  
887 previously<sup>2</sup>. All cells were lysed in an Avestin Emulsiflex system. His<sub>10</sub> proteins were  
888 purified by using Ni-NTA agarose (Qiagen, Catalog # 30230) and GST-SNAP-tSH2Syk  
889 was purified by using glutathione-Sepharose beads (GE Healthcare, Catalog #  
890 17075601) as described previously<sup>2</sup>. Soluble SNAP-tSH2 Syk was generated by  
891 cleaving the GST moiety via the PreScission Protease at 4°C overnight. All proteins  
892 were subjected to gel-filtration chromatography using a Superdex 200 10/300 GL  
893 column (GE Healthcare, Catalog # 17517501) in HEPES-buffered saline (HBS)  
894 containing 50 mM HEPES-NaOH (pH 6.8 for His<sub>10</sub>-CD3 $\zeta$ , His<sub>10</sub>-FcR  $\gamma$ -chain, and GST-  
895 SNAP-tSH2Syk and pH 7.4 for His<sub>10</sub>-Lck Y505F), 150 mM NaCl, 5% glycerol, and 1 mM  
896 TCEP. The monomer fractions were pooled, frozen in liquid nitrogen and stored at -80  
897 °C. All gel-filtered proteins were quantified by SDS-PAGE and Coomassie staining,  
898 using BSA as a standard. To prepare fluorescently labeled tSH2 Syk, 10  $\mu$ M SNAP-  
899 tSH2 Syk was incubated at a 1:2 ratio with SNAP-Cell 505-Star (NEB, Catalog #  
900 S9103S) overnight at 4°C and run over a PD MiniTrap G-25 (GE Healthcare, Catalog #  
901 28-9225-29 AB) column to eliminate excess dye.

902

### 903 **Phosphotyrosine and Phalloidin Staining**

904 To fix and stain preparations described above in bead and bites assays for quantifying  
905 enrichment of phosphotyrosine staining, half the media (~150  $\mu$ l) was gently removed  
906 from the imaging well and replaced with 150  $\mu$ l 6.4% paraformaldehyde solution  
907 (prepared from 32% stock, Electron Microscopy Sciences, Catalog # 50980495) in  
908 tissue culture grade PBS, pH7.2 (Gibco, Catalog # 20012050). Cells were fixed for 15  
909 minutes in a 37°C incubator with CO<sub>2</sub>. After fixation cells were washed 2x with PBS and  
910 permeabilized/blocked for 60 min at room temperature in freshly prepared, filter  
911 sterilized PBS + 5% FBS + 0.1% w/v saponin (PFS solution). After permeabilization,  
912 cells were washed 2x 3 min with PFS solution. Following block, cells were incubated  
913 with 1:100 dilution of mouse anti-phosphotyrosine (pTyr) antibody to stain pan-pTyr  
914 (Santa Cruz, Catalog # PY20) diluted in PFS solution in the dark for 60 min at room

915 temperature then washed 3x 5 min in PFS solution. Washed cells were incubated with a  
916 1:500 dilution of goat anti-mouse Alexa Fluor 647 antibody (Thermo/Molecular Probes,  
917 Catalog # A21236) in PFS solution in the dark for 60 min at room temperature. Wells  
918 were then washed 3x 5 min in PFS solution. Cells were covered in 200  $\mu$ l PBS. If not  
919 imaged immediately samples were wrapped in parafilm and foil and stored at 4°C prior  
920 to microscopy. Phosphotyrosine enrichment at the synapse was calculated by dividing  
921 the mean Alexa Fluor 647 signal of a 5 pixel linescan at the synapse with bead or cell  
922 by a 5 pixel linescan on the cortex. For phalloidin staining, cells were fixed with 4% PFA  
923 for 15 minutes at room temperature, blocked and permeabilized with 5% BSA in TBS  
924 with 0.5% triton X overnight, and incubated with AlexaFluor 647 Phalloidin  
925 (Thermo/Molecular Probes, Catalog # A22284) for 20 minutes. Cells were then washed  
926 with PBS, imaged and quantified using the method described above. Each data point  
927 represents a single cell, and the graphs reflect pooled results from three biological  
928 replicates.

929

### 930 **Ovalbumin Antibody Staining**

931 To fix and stain preparations described above for ovalbumin staining, half the media  
932 (~150  $\mu$ l) was gently removed from the imaging well and replaced with 150  $\mu$ l 8%  
933 paraformaldehyde solution (prepared from 32% stock, Electron Microscopy Sciences,  
934 Catalog # 50980495) in tissue culture grade PBS, pH7.2 (Gibco, Catalog # 20012050).  
935 Cells were fixed for 10 minutes in a 37°C incubator with CO<sub>2</sub>. After fixation cells were  
936 washed 2x with PBS and permeabilized/blocked for 60 min at room temperature in  
937 freshly prepared, filter sterilized PBS + 0.1% w/v casein + 0.1% w/v saponin (PCS  
938 solution). After permeabilization, cells were washed 1x 3 min with PCS solution and  
939 blocked for 1hr at room temperature in PCS. Following block, cells were incubated with  
940 1:100 dilution of rabbit anti-ovalbumin (OVA) antibody to stain OVA (Thermo/Pierce,  
941 Catalog # PA1-196) diluted in PCS solution overnight at 4°C. Washed cells were  
942 incubated with a 1:200 dilution of goat anti-rabbit Alexa Fluor 647 antibody  
943 (Thermo/Molecular Probes, Catalog # A21235) and 3.3 nM 488 phalloidin (dissolved at  
944 6.6  $\mu$ M in methanol) in PCS solution in the dark for 60 min at room temperature. Wells  
945 were then washed 3x 5 min in PCS solution. Cells were covered in 200  $\mu$ l PBS and

946 immediately imaged. Ovalbumin signal was quantified as the corrected total cell  
947 fluorescence (CTCF).  $CTCF = \text{Integrated Density} - \text{Area of Selected Cell} * \text{Mean}$   
948  $\text{Fluorescence of 3 Background Readings}$ . Each data point represents a single cell, and  
949 the graphs reflect pooled results from three biological replicates.

950

### 951 **Image processing and analysis**

952 All image quantification was done on raw, unedited images. All images in figures were  
953 first analyzed in ImageJ, where a single Z-slice at the center of the cell was extracted.  
954 The image intensities were scaled to enhance contrast and cropped in Photoshop. For  
955 movies, background was subtracted in Fiji using a rolling ball radius of 50  $\mu\text{m}$  and  
956 bleach corrected using the Histogram Matching plug in.

957

### 958 **Statistics**

959 All statistical analysis was performed in Prism 6.0 (GraphPad, Inc.). The statistical test  
960 used is indicated in each figure legend. Error bars throughout the paper denote 95%  
961 confidence intervals of the mean. \*\*\* indicates  $p < 0.0001$ ; \*\* indicates  $p < 0.001$  and \*  
962 indicates  $p < 0.01$ .

963

### 964 **Methods References**

965

- 966 1. Mayordomo, J.I. *et al.* Bone marrow-derived dendritic cells pulsed with synthetic  
967 tumour peptides elicit protective and therapeutic antitumor immunity. *Nat. Med.*  
968 (1995). doi:10.1038/nm1295-1297
- 969 2. Hui, E. and Vale, R.D. In vitro membrane reconstitution of the T-cell receptor  
970 proximal signaling network. *Nat. Struct. Mol. Biol.* (2014). doi: 10.1038/nsmb.2762
- 971 3. Edelstein, A. *et al.* Computer control of microscopes using  $\mu\text{Manager}$ . *Curr.*  
972 *Protoc. Mol. Biol.* (2010). doi:10.1002/0471142727

973

974

Figure 1: Identification of intracellular signaling region for CAR-P




Figure 2: CAR-P expression drives specific engulfment of diverse beads




Figure 3: A phosphorylated ITAM at the cell-target synapse drives engulfment




Figure 4: CAR-P promotes trogocytosis and whole cell eating

a. J774A.1 Macrophages









Figure 1- figure supplement 1: Expression of CAR-P constructs in macrophages




Figure 3- figure supplement 1: F-actin is enriched at the cell-target synapse




Figure 4- figure supplement 1: CAR-P localizes with pTyr at synapse with Raji B cell





Figure 4- figure supplement 2: NIH 3T3 cells internalize Raji B cell bites

NIH 3T3 Fibroblasts





Figure 4- figure supplement 3:

Oponsonization by an anti-CD47 antibody enhances whole cell internalization through CAR-P




Figure 4- figure supplement 4: CAR-Ps promote internalization of cancer antigen

